nach oben

Erschienen in:

01.04.2021 | Review Article

Exosomes and cancer: from molecular mechanisms to clinical applications

verfasst von: Ameneh Jafari, Amirhesam Babajani, Meghdad Abdollahpour-Alitappeh, Nayebali Ahmadi, Mostafa Rezaei-Tavirani

Erschienen in: Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Exosomes are extracellular nanovesicles secreted from almost all types of normal and cancer cells. Collective evidence suggests that exosomes participate in cell–cell communication via transmitting their cargo, including nucleic acids, proteins, and metabolites to recipient cells. Tumor-derived exosomes (TEXs) play prominent roles in the regulation of molecular pathways in malignancies. Internalization of exosomes by tumor cells affects cellular pathways and several cancer hallmarks, including reprogramming of stromal cells, modulating immune responses, reconstructing extracellular matrix architecture, or even endowing tumor cells with drug features resistance. The unique biogenesis pathways of exosomes, their composition, low immunogenicity, and nontoxicity, together with their ability to target tumor cells, bring them up as an attractive vesicles for cancer therapy. Thus, understanding the molecular mechanisms of exosomes' participation in tumorigenesis will be critical for the next generation of cancer therapeutics. This review aims to summarize the exosomes' roles in different mechanisms underlying cancer progression for the rational design of tailored strategies against this illness. The present study also highlights the new findings on using these smart vesicles as therapeutic targets and potential biomarkers. Recent advances in exosome biology will open up new, more effective, less invasive, and more individualized clinical applications for treating cancer patients.

Nur mit Berechtigung zugänglich

Jafari A, Rezaei-Tavirani M, Farhadihosseinabadi B, Zali H, Niknejad H. Human amniotic mesenchymal stem cells to promote/suppress cancer: two sides of the same coin. Stem Cell Res Ther. 2021;12:126. https://doi.org/10.1186/s13287-021-02196-x.CrossRefPubMedPubMedCentral

Babajani A, Soltani P, Jamshidi E, Farjoo MH, Niknejad H. Recent advances on drug-loaded mesenchymal stem cells with anti-neoplastic agents for targeted treatment of cancer. Front Bioeng Biotechnol. 2020;8:748. https://doi.org/10.3389/fbioe.2020.00748.CrossRefPubMedPubMedCentral

Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5:145. https://doi.org/10.1038/s41392-020-00261-0.CrossRefPubMedPubMedCentral

Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262:9412–20.CrossRefPubMed

Vidal M. Exosomes: revisiting their role as “garbage bags.” Traffic. 2019;20:815–28. https://doi.org/10.1111/tra.12687.CrossRefPubMed

Wu R, Gao W, Yao K, Ge J. Roles of exosomes derived from immune cells in cardiovascular diseases. Front Immunol. 2019;10:648. https://doi.org/10.3389/fimmu.2019.00648.CrossRefPubMedPubMedCentral

Jamshidi E, Babajani A, Soltani P, Niknejad H. Proposed mechanisms of targeting COVID-19 by delivering mesenchymal stem cells and their exosomes to damaged organs. Stem Cell Rev Rep. 2021. https://doi.org/10.1007/s12015-020-10109-3.CrossRefPubMedPubMedCentral

Barceló M, Castells M, Bassas L, Vigués F, Larriba S. Semen miRNAs contained in exosomes as non-invasive biomarkers for prostate cancer diagnosis. Sci Rep. 2019;9:13772. https://doi.org/10.1038/s41598-019-50172-6.CrossRefPubMedPubMedCentral

Sagredo AI, Sepulveda SA, Roa JC, Oróstica L. Exosomes in bile as potential pancreatobiliary tumor biomarkers. Trans Cancer Res. 2017. https://doi.org/10.21037/tcr.2017.10.37.CrossRef

10.

Kumar SR, Kimchi ET, Manjunath Y, Gajagowni S, Stuckel AJ, Kaifi JT. RNA cargos in extracellular vesicles derived from blood serum in pancreas associated conditions. Sci Rep. 2020;10:2800. https://doi.org/10.1038/s41598-020-59523-0.CrossRefPubMedPubMedCentral

11.

Mirza AH, Kaur S, Nielsen LB, Størling J, Yarani R, Roursgaard M, et al. Breast milk-derived extracellular vesicles enriched in exosomes from mothers with type 1 diabetes contain aberrant levels of microRNAs. Front Immunol. 2019;10:2543. https://doi.org/10.3389/fimmu.2019.02543.CrossRefPubMedPubMedCentral

12.

Pisitkun T, Shen R-F, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004. https://doi.org/10.1073/pnas.0403453101.CrossRefPubMedPubMedCentral

13.

Michael A, Bajracharya SD, Yuen PST, Zhou H, Star RA, Illei GG, et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010;16:34–8. https://doi.org/10.1111/j.1601-0825.2009.01604.x.CrossRefPubMed

14.

Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, et al. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun. 2019;10:254. https://doi.org/10.1038/s41467-018-08109-6.CrossRefPubMedPubMedCentral

15.

Ogorevc E, Kralj-Iglic V, Veranic P. The role of extracellular vesicles in phenotypic cancer transformation. Radiol Oncol. 2013. https://doi.org/10.2478/raon-2013-0037.CrossRefPubMedPubMedCentral

16.

Zhang W, Zhou Q, Wei Y, Da M, Zhang C, Zhong J, et al. The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer. Int J Clin Exp Pathol. 2019;12:2474–84.PubMedPubMedCentral

17.

Zhang Y, Liu F, Yuan Y, Jin C, Chang C, Zhu Y, et al. Inflammasome-derived exosomes activate NF-κB signaling in macrophages. J Proteome Res. 2017;16:170–8. https://doi.org/10.1021/acs.jproteome.6b00599.CrossRefPubMed

18.

Liu Z, Wu C, Zou X, Shen W, Yang J, Zhang X, et al. Exosomes derived from mesenchymal stem cells inhibit neointimal hyperplasia by activating the Erk1/2 signalling pathway in rats. Stem Cell Res Ther. 2020;11:220. https://doi.org/10.1186/s13287-020-01676-w.CrossRefPubMedPubMedCentral

19.

Dovrat S, Caspi M, Zilberberg A, Lahav L, Firsow A, Gur H, et al. 14–3-3 and β-catenin are secreted on extracellular vesicles to activate the oncogenic Wnt pathway. Mol Oncol. 2014;8:894–911. https://doi.org/10.1016/j.molonc.2014.03.011.CrossRefPubMedPubMedCentral

20.

Shelke GV, Yin Y, Jang SC, Lässer C, Wennmalm S, Hoffmann HJ, et al. Endosomal signalling via exosome surface TGFβ-1. J Extracell Vesicles. 2019. https://doi.org/10.1080/20013078.2019.1650458.CrossRefPubMedPubMedCentral

21.

Wang Q, Lu Q. Plasma membrane-derived extracellular microvesicles mediate non-canonical intercellular NOTCH signaling. Nat Commun. 2017;8:709. https://doi.org/10.1038/s41467-017-00767-2.CrossRefPubMedPubMedCentral

22.

Lai RC, Arslan F, Lee MM, Sze NSK, Choo A, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4:214–22. https://doi.org/10.1016/j.scr.2009.12.003.CrossRefPubMed

23.

Liu W, Bai X, Zhang A, Huang J, Xu S, Zhang J. Role of exosomes in central nervous system diseases. Front Mol Neurosci. 2019;12:240. https://doi.org/10.3389/fnmol.2019.00240.CrossRefPubMedPubMedCentral

24.

Zhang S, Hou Y, Yang J, Xie D, Jiang L, Hu H, et al. Application of mesenchymal stem cell exosomes and their drug-loading systems in acute liver failure. J Cell Mol Med. 2020;24:7082–93. https://doi.org/10.1111/jcmm.15290.CrossRefPubMedPubMedCentral

25.

Wang B, Yao K, Huuskes BM, Shen H-H, Zhuang J, Godson C, et al. Mesenchymal stem cells deliver exogenous MicroRNA-let7c via exosomes to attenuate renal fibrosis. Mol Ther. 2016;24:1290–301. https://doi.org/10.1038/mt.2016.90.CrossRefPubMedPubMedCentral

26.

Ye S-B, Li Z-L, Luo D-H, Huang B-J, Chen Y-S, Zhang X-S, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5:5439–52. https://doi.org/10.18632/oncotarget.2118.CrossRefPubMedPubMedCentral

27.

Mittelbrunn M, Sánchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol. 2012;13:328–35. https://doi.org/10.1038/nrm3335.CrossRefPubMedPubMedCentral

28.

Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol. 2012;3:124. https://doi.org/10.3389/fphys.2012.00124.CrossRefPubMedPubMedCentral

29.

Jung MK, Mun JY. Sample preparation and imaging of exosomes by transmission electron microscopy. J Vis Exp. 2018. https://doi.org/10.3791/56482.CrossRefPubMedPubMedCentral

30.

Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017. https://doi.org/10.1038/aps.2017.12.CrossRefPubMedPubMedCentral

31.

Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010. https://doi.org/10.1016/j.jprot.2010.06.006.CrossRefPubMed

32.

Llorente A, Skotland T, Sylvänne T, Kauhanen D, Róg T, Orłowski A, et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim Biophys Acta. 2013;1831:1302–9. https://doi.org/10.1016/j.bbalip.2013.04.011.CrossRefPubMed

33.

Escrevente C, Grammel N, Kandzia S, Zeiser J, Tranfield EM, Conradt HS, et al. Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells. PLoS ONE. 2013;8:e78631. https://doi.org/10.1371/journal.pone.0078631.CrossRefPubMedPubMedCentral

34.

Yoshioka Y, Konishi Y, Kosaka N, Katsuda T, Kato T, Ochiya T. Comparative marker analysis of extracellular vesicles in different human cancer types. J Extracell Vesicles. 2013. https://doi.org/10.3402/jev.v2i0.20424.CrossRefPubMedPubMedCentral

35.

Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–35. https://doi.org/10.1038/nature15756.CrossRefPubMedPubMedCentral

36.

Samsonov R, Shtam T, Burdakov V, Glotov A, Tsyrlina E, Berstein L, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: application for prostate cancer diagnostic. Prostate. 2016;76:68–79. https://doi.org/10.1002/pros.23101.CrossRefPubMed

37.

Urbanelli L, Magini A, Buratta S, Brozzi A, Sagini K, Polchi A, et al. Signaling pathways in exosomes biogenesis, secretion and fate. Genes. 2013;4:152–70. https://doi.org/10.3390/genes4020152.CrossRefPubMedPubMedCentral

38.

Baaklini I, de Gonçalves C, Lukacs GL, Young JC. Selective binding of HSC70 and its co-chaperones to structural hotspots on CFTR. Sci Rep. 2020;10:4176. https://doi.org/10.1038/s41598-020-61107-x.CrossRefPubMedPubMedCentral

39.

Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009;6:267–83. https://doi.org/10.1586/epr.09.17.CrossRefPubMed

40.

Lian Q, Xu J, Yan S, Huang M, Ding H, Sun X, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 2017;27:784–800. https://doi.org/10.1038/cr.2017.54.CrossRefPubMedPubMedCentral

41.

Sharma A, Johnson A. Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J Cell Physiol. 2020. https://doi.org/10.1002/jcp.29153.CrossRefPubMed

42.

Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K, et al. ExoCarta: a web-based compendium of exosomal Cargo. J Mol Biol. 2016;428:688–92. https://doi.org/10.1016/j.jmb.2015.09.019.CrossRefPubMed

43.

Anand PK, Anand E, Bleck CKE, Anes E, Griffiths G. Exosomal Hsp70 induces a pro-inflammatory response to foreign particles including mycobacteria. PLoS ONE. 2010;5:e10136. https://doi.org/10.1371/journal.pone.0010136.CrossRefPubMedPubMedCentral

44.

Quek C, Hill AF. The role of extracellular vesicles in neurodegenerative diseases. Biochem Biophys Res Commun. 2017;483:1178–86. https://doi.org/10.1016/j.bbrc.2016.09.090.CrossRefPubMed

45.

Lim CZJ, Zhang Y, Chen Y, Zhao H, Stephenson MC, Ho NRY, et al. Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition. Nat Commun. 2019;10:1144. https://doi.org/10.1038/s41467-019-09030-2.CrossRefPubMedPubMedCentral

46.

Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, et al. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172–7. https://doi.org/10.1073/pnas.0603838103.CrossRefPubMedPubMedCentral

47.

Wang Y, Xu F, Zhong J-Y, Lin X, Shan S-K, Guo B, et al. Exosomes as mediators of cell-to-cell communication in thyroid disease. Int J Endocrinol. 2020;2020:4378345. https://doi.org/10.1155/2020/4378345.CrossRefPubMedPubMedCentral

48.

Liu H, Chen L, Peng Y, Yu S, Liu J, Wu L, et al. Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. Oncotarget. 2018;9:2887–94. https://doi.org/10.18632/oncotarget.20812.CrossRefPubMed

49.

Zhou Y, Tian T, Zhu Y, Jaffar Ali D, Hu F, Qi Y, et al. Exosomes transfer among different species cells and mediating miRNAs delivery. J Cell Biochem. 2017;118:4267–74. https://doi.org/10.1002/jcb.26077.CrossRefPubMed

50.

Zhang W, Zhou X, Yao Q, Liu Y, Zhang H, Dong Z. HIF-1-mediated production of exosomes during hypoxia is protective in renal tubular cells. Am J Physiol Renal Physiol. 2017;313:F906–13. https://doi.org/10.1152/ajprenal.00178.2017.CrossRefPubMedPubMedCentral

51.

Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A, et al. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 2016;239:162–73. https://doi.org/10.1002/path.4712.CrossRefPubMed

52.

Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110:7312–7. https://doi.org/10.1073/pnas.1220998110.CrossRefPubMedPubMedCentral

53.

Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010;70:9621–30. https://doi.org/10.1158/0008-5472.CAN-10-1722.CrossRefPubMed

54.

Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010;70:1668–78. https://doi.org/10.1158/0008-5472.CAN-09-2470.CrossRefPubMed

55.

Yang W-J, Yan J-B, Zhang L, Zhao F, Mei Z-M, Yang Y-N, et al. Paxillin promotes the migration and angiogenesis of HUVECs and affects angiogenesis in the mouse cornea. Exp Ther Med. 2020;20:901–9. https://doi.org/10.3892/etm.2020.8751.CrossRefPubMedPubMedCentral

56.

Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010;24:3186–95. https://doi.org/10.1096/fj.09-145102.CrossRefPubMedPubMedCentral

57.

Weddell JC, Chen S, Imoukhuede PI. VEGFR1 promotes cell migration and proliferation through PLCγ and PI3K pathways. NPJ Syst Biol Appl. 2018;4:1. https://doi.org/10.1038/s41540-017-0037-9.CrossRefPubMed

58.

DeRita RM, Zerlanko B, Singh A, Lu H, Iozzo RV, Benovic JL, et al. c-Src, insulin-like growth factor I receptor, G-protein-coupled receptor kinases and focal adhesion kinase are enriched into prostate cancer cell exosomes. J Cell Biochem. 2017;118:66–73. https://doi.org/10.1002/jcb.25611.CrossRefPubMed

59.

Guo P, Hu B, Gu W, Xu L, Wang D, Huang H-JS, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003;162:1083–93. https://doi.org/10.1016/S0002-9440(10)63905-3.CrossRefPubMedPubMedCentral

60.

Webb AH, Gao BT, Goldsmith ZK, Irvine AS, Saleh N, Lee RP, et al. Inhibition of MMP-2 and MMP-9 decreases cellular migration and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017. https://doi.org/10.1186/s12885-017-3418-y.CrossRefPubMedPubMedCentral

61.

Sun B, Zhou Y, Fang Y, Li Z, Gu X, Xiang J. Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int J Cancer. 2019;145:1648–59. https://doi.org/10.1002/ijc.32196.CrossRefPubMed

62.

Li R, Wang Y, Zhang X, Feng M, Ma J, Li J, et al. Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol Cancer. 2019;18:18. https://doi.org/10.1186/s12943-019-0948-8.CrossRefPubMedPubMedCentral

63.

Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nat Med. 2012. https://doi.org/10.1038/nm.2775.CrossRefPubMed

64.

Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25:501–15. https://doi.org/10.1016/j.ccr.2014.03.007.CrossRefPubMedPubMedCentral

65.

Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716. https://doi.org/10.1038/ncomms7716.CrossRefPubMed

66.

McCready J, Sims JD, Chan D, Jay DG. Secretion of extracellular hsp90α via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer. 2010. https://doi.org/10.1186/1471-2407-10-294.CrossRefPubMedPubMedCentral

67.

Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–91. https://doi.org/10.1038/nm.2753.CrossRefPubMedPubMedCentral

68.

Hendrix A, Braems G, Bracke M, Seabra M, Gahl W, De Wever O, et al. The secretory small GTPase Rab27B as a marker for breast cancer progression. Oncotarget. 2010;1:304–8. https://doi.org/10.18632/oncotarget.100809.CrossRefPubMedPubMedCentral

69.

Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-Larson N, et al. Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep. 2013;5:1159–68. https://doi.org/10.1016/j.celrep.2013.10.050.CrossRefPubMed

70.

Eddy RJ, Weidmann MD, Sharma VP, Condeelis JS. Tumor Cell invadopodia: invasive protrusions that orchestrate metastasis. Trends Cell Biol. 2017;27:595–607. https://doi.org/10.1016/j.tcb.2017.03.003.CrossRefPubMedPubMedCentral

71.

Bobrie A, Krumeich S, Reyal F, Recchi C, Moita LF, Seabra MC, et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 2012;72:4920–30. https://doi.org/10.1158/0008-5472.CAN-12-0925.CrossRefPubMed

72.

Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X, et al. Tumor Exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 2016;30:243–56. https://doi.org/10.1016/j.ccell.2016.06.021.CrossRefPubMed

73.

Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 2018;17:146. https://doi.org/10.1186/s12943-018-0898-6.CrossRefPubMedPubMedCentral

74.

Wang S, Su X, Xu M, Xiao X, Li X, Li H, et al. Exosomes secreted by mesenchymal stromal/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway. Stem Cell Res Ther. 2019;10:117. https://doi.org/10.1186/s13287-019-1220-2.CrossRefPubMedPubMedCentral

75.

Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang W, et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol Oncol. 2015. https://doi.org/10.1016/j.molonc.2015.01.007.CrossRefPubMedPubMedCentral

76.

Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18:91. https://doi.org/10.1186/s12943-019-1019-x.CrossRefPubMedPubMedCentral

77.

Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, et al. Antagonism of miR-21 Reverses Epithelial-Mesenchymal Transition And Cancer Stem Cell Phenotype Through AKT/ERK1/2 inactivation by targeting PTEN. PLoS ONE. 2012. https://doi.org/10.1371/journal.pone.0039520.CrossRefPubMedPubMedCentral

78.

Ying X, Wu Q, Wu X, Zhu Q, Wang X, Jiang L, et al. Epithelial ovarian cancer-secreted exosomal miR-222–3p induces polarization of tumor-associated macrophages. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.9246.CrossRefPubMedPubMedCentral

79.

Ding J, Xu Z, Zhang Y, Tan C, Hu W, Wang M, et al. Exosome-mediated miR-222 transferring: an insight into NF-κB-mediated breast cancer metastasis. Exp Cell Res. 2018. https://doi.org/10.1016/j.yexcr.2018.05.014.CrossRefPubMed

80.

Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015. https://doi.org/10.1038/nature15376.CrossRefPubMedPubMedCentral

81.

Lin R, Wang S, Zhao RC. Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model. Mol Cell Biochem. 2013. https://doi.org/10.1007/s11010-013-1746-z.CrossRefPubMedPubMedCentral

82.

Sánchez CA, Andahur EI, Valenzuela R, Castellón EA, Fullá JA, Ramos CG, et al. Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.6540.CrossRefPubMedPubMedCentral

83.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33. https://doi.org/10.1126/science.1160809.CrossRefPubMedPubMedCentral

84.

Ward C, Meehan J, Gray ME, Murray AF, Argyle DJ, Kunkler IH, et al. The impact of tumour pH on cancer progression: strategies for clinical intervention. Explor Target Anti-tumor Ther. 2020;1:71–100. https://doi.org/10.37349/etat.2020.00005.CrossRef

85.

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell–derived lactic acid on human T cells. Blood. 2007. https://doi.org/10.1182/blood-2006-07-035972.CrossRefPubMedPubMedCentral

86.

Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013. https://doi.org/10.4049/jimmunol.1202702.CrossRefPubMed

87.

Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284:34211–22. https://doi.org/10.1074/jbc.M109.041152.CrossRefPubMedPubMedCentral

88.

Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife. 2016;5:e10250. https://doi.org/10.7554/eLife.10250.CrossRefPubMedPubMedCentral

89.

Shu SL, Yang Y, Allen CL, Maguire O, Minderman H, Sen A, et al. Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep. 2018;8:12905. https://doi.org/10.1038/s41598-018-31323-7.CrossRefPubMedPubMedCentral

90.

Shephard AP, Yeung V, Clayton A, Webber JP. Prostate cancer exosomes as modulators of the tumor microenvironment. J Cancer Metastas Treat. 2017. https://doi.org/10.20517/2394-4722.2017.32.CrossRef

91.

Ronquist KG, Göran Ronquist K, Ek B, Morrell J, Stavreus-Evers A, Holst BS, et al. Prostasomes from four different species are able to produce extracellular adenosine triphosphate (ATP). Biochim Biophys Acta (BBA). 2013. https://doi.org/10.1016/j.bbagen.2013.05.019.CrossRef

92.

Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol. 2011;187:676–83. https://doi.org/10.4049/jimmunol.1003884.CrossRefPubMed

93.

Escrevente C, Keller S, Altevogt P, Costa J. Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer. 2011;11:108. https://doi.org/10.1186/1471-2407-11-108.CrossRefPubMedPubMedCentral

94.

Qian Y, Wang X, Li Y, Cao Y, Chen X. Abstract 33: NSCLC cells internalize ATPin vitroandin vivousing multiple endocytotic pathways. Mol Cell Biol Genet. 2016. https://doi.org/10.1158/1538-7445.am2016-33.CrossRef

95.

Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417. https://doi.org/10.1038/s41571-020-0341-y.CrossRefPubMedPubMedCentral

96.

Qu J-L, Qu X-J, Zhao M-F, Teng Y-E, Zhang Y, Hou K-Z, et al. Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis. 2009;41:875–80. https://doi.org/10.1016/j.dld.2009.04.006.CrossRefPubMed

97.

Li C, Liu D-R, Li G-G, Wang H-H, Li X-W, Zhang W, et al. CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway. World J Gastroenterol. 2015;21:6215–28. https://doi.org/10.3748/wjg.v21.i20.6215.CrossRefPubMedPubMedCentral

98.

Yang L, Wu X-H, Wang D, Luo C-L, Chen L-X. Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro. Mol Med Rep. 2013;8:1272–8. https://doi.org/10.3892/mmr.2013.1634.CrossRefPubMed

99.

Huang J, Ding Z, Luo Q, Xu W. Cancer cell-derived exosomes promote cell proliferation and inhibit cell apoptosis of both normal lung fibroblasts and non-small cell lung cancer cell through delivering alpha-smooth muscle actin. Am J Transl Res. 2019;11:1711–23.PubMedPubMedCentral

100.

Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, et al. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci U S A. 2014;111:8838–43. https://doi.org/10.1073/pnas.1320769111.CrossRefPubMedPubMedCentral

101.

ExoCarta: Home - Exosome database. http://www.exocarta.org/ (2020). Accessed 18 Nov 2020

102.

Fernandes JV, Cobucci RNO, Jatobá CAN, de Fernandes TAA, de Azevedo JWV, de Araújo JMG. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015;21:527–34. https://doi.org/10.1007/s12253-015-9913-z.CrossRefPubMed

103.

Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep. 2020;10:92. https://doi.org/10.1038/s41598-019-56542-4.CrossRefPubMedPubMedCentral

104.

Shen Y, Guo D, Weng L, Wang S, Ma Z, Yang Y, et al. Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72/HSP105-TLR2/TLR4 pathway. Oncoimmunology. 2017;6:e1362527. https://doi.org/10.1080/2162402X.2017.1362527.CrossRefPubMedPubMedCentral

105.

Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T, et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis. Cancer Res. 2018;78:4586–98. https://doi.org/10.1158/0008-5472.CAN-17-3841.CrossRefPubMed

106.

Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14. https://doi.org/10.1007/s00262-004-0593-x.CrossRefPubMed

107.

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382–6. https://doi.org/10.1038/s41586-018-0392-8.CrossRefPubMedPubMedCentral

108.

Goldvaser H, Gutkin A, Beery E, Edel Y, Nordenberg J, Wolach O, et al. Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker. Br J Cancer. 2017;117:353–7. https://doi.org/10.1038/bjc.2017.166.CrossRefPubMedPubMedCentral

109.

Gutkin A, Uziel O, Beery E, Nordenberg J, Pinchasi M, Goldvaser H, et al. Tumor cells derived exosomes contain hTERT mRNA and transform nonmalignant fibroblasts into telomerase positive cells. Oncotarget. 2016;7:59173–88. https://doi.org/10.18632/oncotarget.10384.CrossRefPubMedPubMedCentral

110.

Corcoran C, Rani S, O’Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014. https://doi.org/10.1002/pros.22848.CrossRefPubMed

111.

Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25:20. https://doi.org/10.1186/s12929-018-0426-4.CrossRefPubMedPubMedCentral

112.

Gradilla A-C, González E, Seijo I, Andrés G, Bischoff M, González-Mendez L, et al. Exosomes as Hedgehog carriers in cytoneme-mediated transport and secretion. Nat Commun. 2014;5:5649. https://doi.org/10.1038/ncomms6649.CrossRefPubMed

113.

Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151:1542–56. https://doi.org/10.1016/j.cell.2012.11.024.CrossRefPubMed

114.

Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ. Exosome release of β-catenin: a novel mechanism that antagonizes Wnt signaling. J Cell Biol. 2010;190:1079–91. https://doi.org/10.1083/jcb.201002049.CrossRefPubMedPubMedCentral

115.

Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A. 2005;102:1933–8. https://doi.org/10.1073/pnas.0401851102.CrossRefPubMedPubMedCentral

116.

Pasquier J, Galas L, Boulangé-Lecomte C, Rioult D, Bultelle F, Magal P, et al. Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells. J Biol Chem. 2012;287:7374–87. https://doi.org/10.1074/jbc.M111.312157.CrossRefPubMedPubMedCentral

117.

Corcoran C, Rani S, O’Brien K, O’Neill A, Prencipe M, Sheikh R, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS ONE. 2012;7:e50999. https://doi.org/10.1371/journal.pone.0050999.CrossRefPubMedPubMedCentral

118.

Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012;227:658–67. https://doi.org/10.1002/jcp.22773.CrossRefPubMed

119.

Dutta S, Reamtong O, Panvongsa W, Kitdumrongthum S, Janpipatkul K, Sangvanich P, et al. Proteomics profiling of cholangiocarcinoma exosomes: a potential role of oncogenic protein transferring in cancer progression. Biochim Biophys Acta. 2015;1852:1989–99. https://doi.org/10.1016/j.bbadis.2015.06.024.CrossRefPubMed

120.

Chen W-X, Liu X-M, Lv M-M, Chen L, Zhao J-H, Zhong S-L, et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS ONE. 2014;9:e95240. https://doi.org/10.1371/journal.pone.0095240.CrossRefPubMedPubMedCentral

121.

Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013;531:8–14. https://doi.org/10.1016/j.gene.2013.08.062.CrossRefPubMed

122.

Yu D-D, Wu Y, Zhang X-H, Lv M-M, Chen W-X, Chen X, et al. Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. Tumour Biol. 2016;37:3227–35. https://doi.org/10.1007/s13277-015-4161-0.CrossRefPubMed

123.

Haney MJ, Zhao Y, Jin YS, Li SM, Bago JR, Klyachko NL, et al. Macrophage-derived extracellular vesicles as drug delivery systems for triple negative breast cancer (TNBC) therapy. J Neuroimmune Pharmacol. 2020. https://doi.org/10.1007/s11481-019-09884-9.CrossRefPubMed

124.

Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Can Res. 2011. https://doi.org/10.1158/0008-5472.can-10-4455.CrossRef

125.

Zhao C, Wang H, Xiong C, Liu Y. Hypoxic glioblastoma release exosomal VEGF-A induce the permeability of blood-brain barrier. Biochem Biophys Res Commun. 2018. https://doi.org/10.1016/j.bbrc.2018.05.140.CrossRefPubMedPubMedCentral

126.

Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. J Control Release. 2014. https://doi.org/10.1016/j.jconrel.2014.07.042.CrossRefPubMed

127.

Coccè V, Franzè S, Brini A, Giannì A, Pascucci L, Ciusani E, et al. In vitro anticancer activity of extracellular vesicles (EVs) secreted by gingival mesenchymal stromal cells primed with paclitaxel. Pharmaceutics. 2019. https://doi.org/10.3390/pharmaceutics11020061.CrossRefPubMedPubMedCentral

128.

Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35:2383–90. https://doi.org/10.1016/j.biomaterials.2013.11.083.CrossRefPubMed

129.

Rivoltini L, Chiodoni C, Squarcina P, Tortoreto M, Villa A, Vergani B, et al. TNF-related apoptosis-inducing ligand (TRAIL)–armed exosomes deliver proapoptotic signals to tumor site. Clin Cancer Res. 2016. https://doi.org/10.1158/1078-0432.ccr-15-2170.CrossRefPubMed

130.

Wall N, Aspe R. Survivin-T34A: molecular mechanism and therapeutic potential. OncoTarget Ther. 2010. https://doi.org/10.2147/ott.s15293.CrossRef

131.

Moroishi T, Hayashi T, Pan W-W, Fujita Y, Holt MV, Qin J, et al. The hippo pathway kinases LATS1/2 suppress cancer immunity. Cell. 2016;167:1525–39. https://doi.org/10.1016/j.cell.2016.11.005.CrossRefPubMedPubMedCentral

132.

Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8:1–11. https://doi.org/10.1186/s13045-015-0220-7.CrossRefPubMedPubMedCentral

133.

Zhang H, Wang Y, Bai M, Wang J, Zhu K, Liu R, et al. Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA. Cancer Sci. 2018. https://doi.org/10.1111/cas.13488.CrossRefPubMedPubMedCentral

134.

Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal. 2013;11:1–10. https://doi.org/10.1186/1478-811X-11-88.CrossRef

135.

Ohno S-I, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically injected exosomes targeted to EGFR deliver antitumor MicroRNA to breast cancer cells. Mol Ther. 2013. https://doi.org/10.1038/mt.2012.180.CrossRefPubMedPubMedCentral

136.

Bu N, Li Q-L, Feng Q, Sun B-Z. Immune protection effect of exosomes against attack of L1210 tumor cells. Leuk Lymphoma. 2006;47:913–8. https://doi.org/10.1080/10428190500376191.CrossRefPubMed

137.

Lee E-Y, Park K-S, Yoon YJ, Lee J, Moon H-G, Jang SC, et al. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS ONE. 2012;7:e33330. https://doi.org/10.1371/journal.pone.0033330.CrossRefPubMedPubMedCentral

138.

Gehrmann U, Hiltbrunner S, Georgoudaki A-M, Karlsson MC, Näslund TI, Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res. 2013;73:3865–76. https://doi.org/10.1158/0008-5472.CAN-12-3918.CrossRefPubMed

139.

Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8 CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med. 2010. https://doi.org/10.1111/j.1582-4934.2009.00851.x.CrossRefPubMed

140.

Mahmoodzadeh Hosseini H, Imani Fooladi AA, Soleimanirad J, Nourani MR, Davaran S, Mahdavi M. Staphylococcal entorotoxin B anchored exosome induces apoptosis in negative esterogen receptor breast cancer cells. Tumour Biol. 2014;35:3699–707. https://doi.org/10.1007/s13277-013-1489-1.CrossRefPubMed

141.

Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3:10. https://doi.org/10.1186/1479-5876-3-10.CrossRefPubMedPubMedCentral

142.

Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:9. https://doi.org/10.1186/1479-5876-3-9.CrossRefPubMedPubMedCentral

143.

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5:e1071008. https://doi.org/10.1080/2162402X.2015.1071008.CrossRefPubMed

144.

Wong C-H, Chen Y-C. Clinical significance of exosomes as potential biomarkers in cancer. World J Clin Cases. 2019. https://doi.org/10.12998/wjcc.v7.i2.171.CrossRefPubMedPubMedCentral

145.

Wang J-C, Begin LR, Berube NG, Chevalier S, Aprikian AG, Gourdeau H, et al. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res. 2007. https://doi.org/10.1158/1078-0432.ccr-06-1692.CrossRefPubMedPubMedCentral

146.

Jang H-I, Lee H. A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med. 2003;35:317–23. https://doi.org/10.1038/emm.2003.43.CrossRefPubMed

147.

Sandfeld-Paulsen B, Jakobsen KR, Bæk R, Folkersen BH, Rasmussen TR, Meldgaard P, et al. Exosomal proteins as diagnostic biomarkers in lung cancer. J Thorac Oncol. 2016. https://doi.org/10.1016/j.jtho.2016.05.034.CrossRefPubMed

148.

Jin H, Liu P, Wu Y, Meng X, Wu M, Han J, et al. Exosomal zinc transporter ZIP4 promotes cancer growth and is a novel diagnostic biomarker for pancreatic cancer. Cancer Sci. 2018;109:2946–56. https://doi.org/10.1111/cas.13737.CrossRefPubMedPubMedCentral

149.

Kimura H, Yamamoto H, Harada T, Fumoto K, Osugi Y, Sada R, et al. CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy. Clin Cancer Res. 2019;25:1936–47. https://doi.org/10.1158/1078-0432.CCR-18-2124.CrossRefPubMed

150.

San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, et al. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol. 2016;27:635–41. https://doi.org/10.1093/annonc/mdv604.CrossRefPubMed

151.

Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156(108–118):e4. https://doi.org/10.1053/j.gastro.2018.09.022.CrossRef

152.

Pigati L, Yaddanapudi SCS, Iyengar R, Kim D-J, Hearn SA, Danforth D, et al. Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS ONE. 2010. https://doi.org/10.1371/journal.pone.0013515.CrossRefPubMedPubMedCentral

153.

Sohn W, Kim J, Kang SH, Yang SR, Cho J-Y, Cho HC, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 2015;47:e184. https://doi.org/10.1038/emm.2015.68.CrossRefPubMedPubMedCentral

154.

Yan S, Jiang Y, Liang C, Cheng M, Jin C, Duan Q, et al. Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer. J Cell Biochem. 2018;119:4113–9. https://doi.org/10.1002/jcb.26609.CrossRefPubMed

155.

Feng Y, Zhong M, Zeng S, Wang L, Liu P, Xiao X, et al. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics. 2019;11:35–51. https://doi.org/10.2217/epi-2018-0123.CrossRefPubMed

156.

Pan D, Chen J, Feng C, Wu W, Wang Y, Tong J, et al. Preferential localization of MUC1 glycoprotein in exosomes secreted by non-small cell lung carcinoma cells. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20020323.CrossRefPubMedPubMedCentral

157.

Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, et al. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur J Cancer. 2017;70:122–32. https://doi.org/10.1016/j.ejca.2016.10.011.CrossRefPubMed

158.

Re MD, Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, et al. PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. Br J Cancer. 2018. https://doi.org/10.1038/bjc.2018.9.CrossRefPubMedPubMedCentral

159.

Saari H, Lázaro-Ibáñez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release. 2015;220:727–37. https://doi.org/10.1016/j.jconrel.2015.09.031.CrossRefPubMed

160.

Melzer C, Rehn V, Yang Y, Bähre H, von der Ohe J, Hass R. Taxol-loaded MSC-derived exosomes provide a therapeutic vehicle to target metastatic breast cancer and other carcinoma cells. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11060798.CrossRefPubMedCentral

161.

Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, et al. Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine. 2017;13:1627–36. https://doi.org/10.1016/j.nano.2017.03.001.CrossRefPubMed

162.

Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL, et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018;14:195–204. https://doi.org/10.1016/j.nano.2017.09.011.CrossRefPubMed

163.

Gomari H, Forouzandeh Moghadam M, Soleimani M. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. Onco Targets Ther. 2018;11:5753–62. https://doi.org/10.2147/OTT.S173110.CrossRefPubMedPubMedCentral

164.

Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med. 2010;14:2655–66. https://doi.org/10.1111/j.1582-4934.2009.00851.x.CrossRefPubMed

165.

Wang J-C, Bégin LR, Bérubé NG, Chevalier S, Aprikian AG, Gourdeau H, et al. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res. 2007;13:2354–61. https://doi.org/10.1158/1078-0432.CCR-06-1692.CrossRefPubMed

Titel: Exosomes and cancer: from molecular mechanisms to clinical applications
verfasst von: Ameneh Jafari
Amirhesam Babajani
Meghdad Abdollahpour-Alitappeh
Nayebali Ahmadi
Mostafa Rezaei-Tavirani
Publikationsdatum: 01.04.2021
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2021
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01491-0

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Exosomes and cancer: from molecular mechanisms to clinical applications

Abstract

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Estimating copy number using next-generation sequencing to determine ERBB2 amplification status

Elevated LINC01550 induces the apoptosis and cell cycle arrest of melanoma

Role of thoracic radiation in extensive stage small cell lung cancer: a NCDB analysis

Tamoxifen in breast cancer survivors with COVID 19: stop or go?

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma

An updated review of epidemiology, risk factors, and management of male breast cancer

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie